Millimetre-sized core-shell hydrogel beads with dual-stimuli (pH and magnetic) sensitiveness were synthesized for drug release in cancer therapeutics. A facile synthesis approach was employed to fabricate gelatin/starch-g-oleic acid/alginate core-shell hydrogel beads HB1 and HB2 (with NiFe2O4 nanoparticles). Microscopic, HRSEM and EDS examinations verified the core-shell morphology of beads, while VSM measurements demonstrated magnetic responsiveness of HB2, with saturation magnetization of 1.89 emu/g. Swelling study in different pH environments ensured the pH-sensitivity of beads. The 5-FU encapsulation efficiency was found to be approximately 32% for both beads. At pH 7.4, the maximum drug release reached 76% for HB1 and 66% for HB2, while at pH 5.5, it was 54% for HB1 and 57% for HB2. The maximum drug release observed was 19% for 5-FU/HB1 and 21% for 5-FU/HB2 in pH 1.5. These results suggest the suitability of the beads for both oral delivery and direct tumour targeting system. Comparatively, hydrogel beads without NiFe2O4 NPs exhibited higher release over time than those containing NiFe2O4 NPs, attributed to increased core crosslinking density. At 300 min, 350 G magnetic field increased drug release of HB2 by 13%. The mechanism behind the drug release process was explained by Peppas-Sahlin kinetic, which showed that polymer relaxation dominates the drug release process with minimal contribution from Fickian diffusion. Moreover, cytotoxicity study using MCF-7 cells revealed that 5-FU loaded HB2 effectively induces cancer cell death, with an IC50 of 7.7 µg/ml. Biocompatibility and hemocompatibility of the hydrogel systems were also demonstrated, thereby highlighting their promise for cancer therapeutics.
扫码关注我们
求助内容:
应助结果提醒方式:
